- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
Futura provides update on efficacy study of MED2002
17 November 2015 • Author: Victoria White
Futura Medical has provided an update on progress of its pivotal efficacy study of MED2002, the Company’s novel gel for the treatment of erectile dysfunction (ED).
Futura says recruitment of patients for the study is proceeding well, with 118 patients having enrolled in the study to date. Once enrolled, the clinical test period per patient is approximately three months. A total of 192 patients are expected to take part in the trial, which remains on track to deliver headline results next year.
All of the patients recruited to date have been enrolled in London and, as previously advised, further recruitment sites within the EU have been identified. Ethics approvals for these sites have now been obtained and pending regulatory approval overseas recruitment is expected to commence in 2016.
Futura added that no serious adverse events have been recorded to date among the patients who have participated in the trial, which is of a randomised, placebo-controlled, double blind, home use, crossover design. Because the trial is blinded, efficacy data will not be available until the end of the trial.
Futura “pleased” by the pace of recruitment
The primary endpoint of the study is the efficacy of MED2002 in male subjects self-diagnosed with ED using the erectile function domain of the International Index of Erectile Function (IIEF). The IIEF is a well validated measure of erectile function and was used for the approval of PDE5 inhibitors, such as Viagra. Secondary endpoints in the trial include the speed of onset.
James Barder, Futura’s Chief Executive, commented: “We are pleased by the pace of recruitment to this pivotal trial of MED2002 in erectile dysfunction. MED2002 is a novel, topical gel with potential benefits including the speed of onset of action and the use of the product as part of sexual foreplay. The current trial is focused on demonstrating efficacy and remains on track to deliver headline results by the end of the first half next year.”
MED2002 is based on the active compound Glyceryl Trinitrate (GTN) within a patented gel delivery system, DermaSys. GTN is a potent vasodilator and has been used for the treatment of angina and associated cardio-vascular defects for more than 40 years, where it has been determined to be a safe and effective drug with a known side-effect profile.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific ReAgent Russell Finex Limited Sentronic GmbH Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited WITec GmbH Xylem Analytics YMC Europe GmbH Yusen Logistics